🔗 Share this article

As the United States undertakes sweeping changes to its vaccine schedules, a particular individual appears in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who first made her name by casting doubt on Covid vaccinations during the pandemic and has concentrated on possible fatalities following Covid immunization in her short time at the Food and Drug Administration.

Proposed Overhauls to Childhood Immunization Schedule

Agency leaders had intended to unveil sweeping changes to the childhood vaccination calendar recently, synchronizing the US with Denmark’s vaccine program, it is understood – a significant shift that would put the US out of alignment with a large portion of the international standard with little proof for public health gain. The planned update has been delayed until the next year.

Instead of the director of the vaccine center, Høeg is scheduled to speak at the gathering. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the office this calendar year.

A New Direction at the FDA

Høeg's temporary position could signify a strengthened alliance between the pharmaceutical and biologics branches as Høeg and Prasad consolidate power at the agency – and it suggests a renewed priority upon reevaluating already-approved vaccines at the FDA.

Dr. Høeg has frequently advocated for halting specific childhood vaccine recommendations in the US so as to align more similar to the Danish model, a society with comprehensive healthcare and a citizenry roughly the size of Wisconsin’s.

To date public appearances, she has continued to focus on vaccination policy – typically the responsibility of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Doubts Over Background

The appointee has little discernible experience in pharmaceutical research, regulation or management, which has been customary for former heads of the CBER. She has worked at the FDA as a senior adviser to the commissioner and CBER since spring.

“She appears not to have the necessary background” for leading the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She has not conducted a clinical trial. She is not versed in leading a large organization. She is not an expert in pharmaceutical oversight.”

Former commissioners of CBER would “be deeply familiar with laws and regulations and the science of medication creation”, said Dr. Janet Woodcock. “Frankly, she doesn’t have the type of experience that former directors who led CBER have had.”

CDER has an immense portfolio at the FDA, she pointed out.

“Everybody just focuses on the innovative therapies, but the generic program clears a multitude of off-brand pharmaceuticals. There’s a biologic copycat branch, OTC medication office and more, and each of these must be looked after,” Dr. Woodcock explained. “The thing you overlook, that is precisely what that I always told people is going to cause problems.”

There is also, a major management element to the job, which oversees more than 5,000 employees. “It’s a massive management job, if you perform it correctly,” Woodcock added.

Agency Reaction and Controversial Initiatives

In response to inquiries about Høeg’s credentials and whether this appointment represents greater collaboration among FDA leaders on vaccines, a press secretary responded that the “inquiries stem from inaccurate presumptions”.

“Her experience matches the functions of her job,” the official said, pointing to the period Dr. Høeg spent counseling the FDA commissioner on “drug safety and approval science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Dr. Høeg inherits the commissioner’s recently launched priority voucher program, a controversial expedited drug-approval program that allegedly troubled her predecessors. “How are these therapies being chosen for this expedited pathway? Who makes the choices?” Dr. Howard asked. “There’s a lot of confidentiality occurring at the regulatory body right now.”

Broadly speaking, he stated, “the FDA looks to be trending towards laxer oversight of pharmaceuticals, with the exception of immunizations.”

Established History on Immunizations

Regarding immunizations, Dr. Høeg has a more documented, if troubling, track record, some experts said. She released a study using unconfirmed public submissions to assess the rate of heart inflammation following Covid vaccination. She advised the state of Florida surgeon general Dr. Joseph Ladapo, who allegedly have changed statistics to indicate Covid vaccinations are more dangerous than they are.

Among her “policy goals” for the incoming federal leadership encompassed revising rules for recently developed shots and ending “non-essential” immunizations, she said following the vote on a podcast. At the FDA, Høeg has allegedly proposed preventing young men from receiving Covid vaccinations.

“She is an all-around ideologue who starts off with her conclusions and works backwards to accommodate the evidence in a highly disingenuous, untruthful manner,” Dr. Howard said.

Taking Control and a “Campaign of Retribution”

Høeg joined fellow skeptics, {like|